A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

PHASE1CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 16, 2021

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
Asthma
Interventions
DRUG

AZD8630

Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.

DRUG

Placebo

Participants will receive Inhaled or IV doses of placebo as per the arm they are assigned.

Trial Locations (29)

10119

Research Site, Berlin

21162

Research Site, White Marsh

22927

Research Site, Großhansdorf

23552

Research Site, Lübeck

27607

Research Site, Raleigh

33030

Research Site, Homestead

33122

Research Site, Miami

33144

Research Site, Miami

33155

Research Site, Miami

33173

Research Site, Miami

33175

Research Site, Miami

39120

Research Site, Magdeburg

43617

Research Site, Toledo

48105

Research Site, Ann Arbor

60596

Research Site, Frankfurt

65187

Research Site, Wiesbaden

79903

Research Site, El Paso

83706

Research Site, Boise

85283

Research Site, Tempe

91206

Research Site, Glendale

93301

Research Site, Bakersfield

95117

Research Site, San Jose

97202

Research Site, Portland

02747

Research Site, North Dartmouth

BD9 6RJ

Research Site, Bradford

HA1 3UJ

Research Site, London

W12 0HS

Research Site, London

M23 9QZ

Research Site, Manchester

PO6 3LY

Research Site, Portsmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY